BioNTech Results Presentation Deck

2 iNeST: BNT122 recent AACR data update Ongoing Phase 1 trial of iNeST presented at AACR 2020 Blood and tumor biopsy collection 12 5' Cap analog Sequencing Evaluation of BNT122 safety & feasibility with/without Tecentriq in > 10 indications 5' UTR SEC RNA backbone Bioinformatics Neoantigen Prediction RNA-lipoplex manufacturing NEOANTIGENS Innate Immune Stimulation Intrinsic TLR7/8 agonist ● 3' UTR ● MITD- ● Cold storage and distribution AAAA Poly(A) tail Data from ongoing Phase 1 trial in heavily pre-treated, PD-1 low patients across multiple tumor types Demonstrated ability to elicit significant T cell responses of both effector and memory phenotype as monotherapy and in combination (multiple patients with > 5% T cell response per neoepitope) RNA backbone Treatment-related adverse events were primarily transient systemic reactions, manifesting as low grade CRS, IRR or flu-like symptoms Initial signals of clinical activity observed in monotherapy dose-escalation cohort (1 CR, 12 SD) Intravenous administration Single-stranded mRNA Antigen Expression Up to 20 neoantigens (2 decatopes) BNT122 induces CD8+ T cells in CPI-sensitive and CPI-insensitive tumor types PE Multimer Patient With Prostate Cancer Treated With RO7198457 (38 µg) C3D1 2.49% Baseline 0.03% 97.79% Te rring m BV605 Multimer CCR7 C2D1 1.95% 95.69% CD45RO Tem 195.88% Phenotype of MHC Multimer-Positive Cells Effector Memory Phenotype Tem T₁₁ 87.7% pang ang PD-1 PD-1+ Cells PD-1+ CD8 T cells 99.6% CD8 C4D1 4.7% 193.89% per TOME TITT BNT122 induces CD8+ T cell Infiltrates in tumors Frequency of TCRs (log,0) in Baseline Tumor -1.6- -1.8- -2- -2.2 -24 -2.6 -2.8- -3.2- -34- -3.6 O OCCIOXPED contentco BLOOO 0 O он рос CO DO 0 00 Ф О RO7198457-specific TCRs Other TCRs OOOOO 32-36-34-32 -3 -28 -26-24-22 -2 -18-16-4 O RO7198457-specific TCRs are present only in post-treatment tumor. Frequency of TCRs (log 10) in Post-Treatment Tumor BIONTECH

View entire presentation